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Genome-wide mRNA expression correlates of viral control in
CD4+ T-cells from HIV-1-infected individuals
Abstract
There is great interindividual variability in HIV-1 viral setpoint after seroconversion, some of which is
known to be due to genetic differences among infected individuals. Here, our focus is on determining,
genome-wide, the contribution of variable gene expression to viral control, and to relate it to genomic
DNA polymorphism. RNA was extracted from purified CD4+ T-cells from 137 HIV-1 seroconverters,
16 elite controllers, and 3 healthy blood donors. Expression levels of more than 48,000 mRNA
transcripts were assessed by the Human-6 v3 Expression BeadChips (Illumina). Genome-wide SNP data
was generated from genomic DNA using the HumanHap550 Genotyping BeadChip (Illumina). We
observed two distinct profiles with 260 genes differentially expressed depending on HIV-1 viral load.
There was significant upregulation of expression of interferon stimulated genes with increasing viral
load, including genes of the intrinsic antiretroviral defense. Upon successful antiretroviral treatment, the
transcriptome profile of previously viremic individuals reverted to a pattern comparable to that of elite
controllers and of uninfected individuals. Genome-wide evaluation of cis-acting SNPs identified genetic
variants modulating expression of 190 genes. Those were compared to the genes whose expression was
found associated with viral load: expression of one interferon stimulated gene, OAS1, was found to be
regulated by a SNP (rs3177979, p = 4.9E-12); however, we could not detect an independent association
of the SNP with viral setpoint. Thus, this study represents an attempt to integrate genome-wide SNP
signals with genome-wide expression profiles in the search for biological correlates of HIV-1 control. It
underscores the paradox of the association between increasing levels of viral load and greater expression
of antiviral defense pathways. It also shows that elite controllers do not have a fully distinctive mRNA
expression pattern in CD4+ T cells. Overall, changes in global RNA expression reflect responses to viral
replication rather than a mechanism that might explain viral control.
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study represents an attempt to integrate genome-wide SNP signals with genome-wide expression profiles in the search for
biological correlates of HIV-1 control. It underscores the paradox of the association between increasing levels of viral load
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Introduction
There has been a recent effort to identify the genomic determinants
of susceptibility to HIV-1 infection, control of viral replication, and
disease progression [1]. Genetic analyses have identified over the years
a number of validated variants in candidate genes, while a recent
genome-wide association study [2] highlighted the dominant role of
variants in the MHC region in the control of viral setpoint (the steady
state of viral replication after infection) and disease progression. Other
genome-wide studies [3–5] confirmed the variants identified in the first
genome-wide analysis. These variants collectively explain up to about
13% of the variation in viral setpoint, indicating that other biological
determinants of control have yet to be identified. Here our focus is on
determining the contribution of variable gene expression to viral
control, and to relate it to genomic DNA polymorphism.
There have been a number of transcriptome studies in HIV-1
target cells (CD4+ T cells, monocytes/macrophages), non-targets
such as NK cells and B cells, and of dendritic cells and total
peripheral blood mononuclear cells (PBMCs) (reviewed in [6], and
recent publications [7–11]). These studies provide insight into gene
expression changes associated with virus replication and persis-
tence. Studies are limited by the number of genes interrogated, or
by the number of individuals investigated. These limits notwith-
standing, microarray data have yielded novel mechanisms of HIV-
mediated pathogenesis. Transcriptome analyses of cell lines
transfected with individual viral proteins or mutant viruses have
also been reported (reviewed in [6]).
This study aims at coupling a large scale assessment of gene
expression in purified CD4+ T cells from HIV-1 infected
individuals, with genome-wide genotype data tested for association
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with viral setpoint. Integrating gene expression data with results
from genome-wide association studies may help prioritize fine-
mapping efforts and provide shortcuts to disease biology [12].
Therefore, the goals of the study are the description of the
expression program associated with HIV-1 in vivo, the identifica-
tion of mRNAs that are differentially expressed in individuals that
present effective control of viral replication, and the search for cis-
acting variation in differentially expressed genes. Expression
polymorphism due to single nucleotide polymorphisms (SNPs)
that influence mRNA levels has received increasing attention for
the understanding of phenotypes in health and disease (reviewed in
[12]). Genome-wide screens, most generally done in cell lines,
have established the relevance of cis-acting SNPs in expression
polymorphism [13]. However, little is known regarding expression
polymorphism and HIV-1 disease.
In order to have power to detect correlations, we have considered
a large sample set of purified CD4+ T cells from individuals with
known date of infection and carefully determined viral load results.
Transcription analysis was done at the time of viral setpoint, so that
samples are representative of the steady-state replication for a given
individual, and across the full range of viral setpoint in an infected
population. For a large subset of participants, we also established the
transcription profile after initiation of antiretroviral therapy (ART)
to assess the modulation of expression upon effective control of
viremia. Thus, this study represents a first attempt at assessing,
genome-wide, the genotype-to-transcriptome-to-clinical phenotype
associations in HIV-1 disease.
Results
Transcriptome profile and viral setpoint analysis
We identified 298 hybridization probes that were significantly
correlated with viral load (FDR-adjusted p-value,0.01). This
resulted in a list of 260 genes, since multiple probes are used for
some of the genes. The majority of these (n = 209) were positively
associated with viral setpoint, while a smaller group (n= 51) was
negatively associated (Supplementary Table S1). We used
(unsupervised) clustering to group the expression profiles of the
samples for these 260 genes, and found that they showed distinct
behavior in individuals with effective virus control (reflected in low
viral setpoint) as compared with individuals showing poor control
of viral replication (Figure 1). In an analysis that considered
viral load at the precise date of transcriptome analysis instead of
setpoint, the results were comparable, implying that the expression
profile is representative for the period of analysis (three months to
three years after seroconversion), Figure 1. The analysis included
various parameters as covariates (clinical center, gender, age, CD4
T cell viability and laboratory date, and microarray chip batch -
sentrix ID). The CD4 T cell value at the time of sampling was
found to be closely correlated with viral setpoint (Pearson’s
correlation of 20.5 and a p-value = 1.195e-10), which made
difficult to separate their effects on the data. The 149 genes that
are shared between analysis using CD4 T cell count, and the
analysis using viral setpoint are indicated in Supplementary
Table S1.
The main gene clusters exhibiting a positive correlation with
viral setpoint (i.e., increasing gene expression with increasing viral
load), as defined by STRING, DAVID and IPA, were the
interferon pathway, the proteasome, and cell cycle genes (Figure 2
and Supplementary Table S2, S3). Conversely, among genes
that exhibited a negative correlation with viral setpoint (Supple-
mentary Table S1B), no pathway enrichment was identified. A
separate analysis that used a gene-by-gene modeling approach
resulted in a list of significant genes that was shorter (44 genes) but
highly concordant with the output of the empirical Bayes analysis
described above (Supplementary Table S4): we therefore used
the empirical Bayes results for subsequent analyses. Because the
CD4+T cell composition may vary depending on the degree of
viral replication [7], we re-analyzed the data controlling for CD25
expression (encoding IL2RA as marker of activation), or CD62L,
CD40L, CD11a, and CD27 (markers that distinguish naive from
memory CD4+ T cells). Although several additional significant
genes were found using each of the above markers as covariates,
the overall expression profile did not vary significantly (see for
example data from analysis adjusted by CD25 in Supplementary
Table S5). These analyses indicate the existence of a clear
expression program associated with high viral load, but fail to
identify definite gene networks associated with viral control.
Analysis of genes of the interferon response pathways
We observed a linear association between increasing expression
of interferon signaling and interferon-stimulated genes (ISGs) and
increasing viral setpoint. We compiled a list of 40 genes implicated
in the interferon response [14] (Supplementary Table S6).
Seventeen genes were significantly associated with viral setpoint
after FDR adjustment at the 0.01 level, and 12 were associated at a
p-value of 0.05. These 29 genes comprise most of the signaling and
ISGs, but notably exclude the interferon genes themselves and the
interferon receptors (Figure 3). This analysis points to a de-
regulated interferon response that associates with an ineffective
antiviral response.
Analysis of genes associated with HIV-1 life cycle and
pathogenesis
We similarly examined in detail a list of selected genes reported
to be involved in HIV-1 life cycle or pathogenesis (see Methods for
explanation of candidate selection) [15]. Of this list, 138 genes
were matched to probes, with four having a FDR-adjusted
significant association with viral setpoint, p-value ,0.01: TRIM22,
IRF7, RANBP1, and APOBEC3G. An additional 12 genes had
FDR-adjusted p-values ,0.05, and a further 26 had nominal
p-values ,0.05 (Supplementary Table S7). Genes of the
intrinsic cellular defense against retroviruses (TRIM5a, TRIM22,
TRIM19/PML, APOBEC3G, APOBEC3F, APOBEC3H, PPIA/
Cyclophilin A, BST2/Tetherin) were all upregulated with increasing
viral load, which is consistent with their general dependence on
the interferon pathways. A number of chemokines and chemokine
Author Summary
There has been recent progress in understanding the
genetic factors that modulate susceptibility to HIV-1
infection. Genetic variation explains to a certain extent
differences in disease progression among individuals. Less is
known regarding the contribution of differences in gene
expression to viral control. The present study evaluated,
genome-wide, gene expression levels in CD4+ T cell, the
main target of HIV-1. Thereafter, it searched for genetic
variants that would modify gene expression. Specific
expression profiles associated with high levels of vire-
mia—in particular, the upregulation of genes of the antiviral
defense. In contrast, no expression profile associated with
effective viral control. Multiple genetic variants modulated
gene expression in CD4+ T cells; however, none had a
strong influence on viral control. This integrated genome-
wide assessment suggests that viral replication drives gene
expression rather than expression pointing to mechanisms
of viral control.
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Figure 1. Transcriptome analysis in CD4+ T cells from HIV-infected untreated individuals. Gene clusters are presented on the left. In total,
260 genes are differentially expressed (at adjusted p,0.01) in association with viral load in CD4+ T cells during in vivo HIV-1 infection. Patient clusters
are presented at the top for untreated individuals. Clustering was performed on the Spearman correlation coefficient. The phenotype is presented at
the bottom, as log10 viral setpoint in gray, and log10 viral load at time of sample collection in red. A smooth of the setpoint viral load values is
depicted by the black line. The red rectangle surrounds a cluster of individuals characterized by low viral load (mean Log10 viral setpoint = 2.6), and
including several ‘‘elite controllers’’ – individuals that spontaneous control viral replication in the absence of treatment. The blue rectangle identifies a
cluster of individuals with high viral setpoint (mean Log10 viral setpoint = 4.4). The remaining clusters illustrate the heterogeneity of transcription
profile across the range of viral load values.
doi:10.1371/journal.ppat.1000781.g001
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PLoS Pathogens | www.plospathogens.org 3 February 2010 | Volume 6 | Issue 2 | e1000781
receptors were also positively modulated with increasing viremia.
We also identified differentially expressed genes that are present in
both the current analysis and studies that used siRNA or shRNA
to identify HIV-1 dependency factors [16–19] (Supplementary
Table S8).
Changes in transcriptome profile after treatment
The significant association of a number of genes and pathways
with viral setpoint was further assessed by observing the changes in
transcriptional profile in CD4+ T cells after viral suppression. We
found statistical support for differential expression of 247 probes
(FDR-adjusted p-value ,0.01) between treated and untreated-
noncontroller individuals. The list of genes involved had an
extensive overlap with the list of genes associated with viral
setpoint in the transcriptome analysis above (Supplementary
Table S9). The list also shares 97 genes with the recent study by
Li et al. [20] on changes in the lymph node transcriptome profile
upon initiation of ART. This analysis indicates that successful
treatment appears able to recapitulate the cellular state of a well-
controlled individual, since we did not find support for any probes
being differently expressed between successfully treated and
untreated-controller individuals.
Comparison with uninfected individuals
To compare the treated and untreated individuals with
uninfected individuals, we clustered the expression profiles from
Figure 2. Predicted interaction networks of genes differentially expressed during HIV-1 infection. Differentially expressed genes are
depicted: links have been predicted using STRING (http://string.embl.de/). Predicted interactions are depicted according to the type of available
evidence. The interactions (see color labels) include direct (physical) and indirect (functional) associations; they are derived from four sources:
genomic context, high-throughput experiments, conserved coexpression, and previous knowledge from literature.
doi:10.1371/journal.ppat.1000781.g002
Genome-Wide mRNA Expression and HIV
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samples from a selected group of individuals, including elite
controllers (viral load ,50 copies/ml), samples from successfully
treated individuals and their paired untreated samples, and from
the three uninfected individuals (measured in triplicate, one
triplicate failed analysis). For this, we restricted analysis to the 260
genes found to be differently expressed by viral setpoint. As shown
in Figure 4, both the successfully treated and uninfected
individuals tended to cluster with the controllers individuals.
Two of the individuals from healthy donors were most tightly
grouped with several of the untreated individuals that have the
lowest level of virus at setpoint (i.e. the elite controllers), while one
uninfected individual showed a profile that is less extreme, but still
most similar to the viral control profile. Treated individuals also
preferentially grouped with the viral control pattern, although the
majority showed a mid-range expression level and a smaller
fraction grouped with elite controllers and uninfected individuals.
A bootstrapping analysis showed support (p-value 0.06) for the
consistency of the top-level groupings with one group containing
all the uninfected individuals and the majority of the treated and
elite controller individuals, while the other group contained mostly
non-controller individuals. This indicates that the expression levels
of individuals with the best viral control closely resemble those of
uninfected individuals.
Screen for cis-acting SNPs regulating transcript
expression levels
Among a total of 1.3 million association tests comparing
399,626 gene-centric SNPs (some SNPs were within 100 kb of
multiple transcripts) with 28,828 individual probes measuring a
total of 18,059 unique transcripts, we detected 782 study-wide
significant associations (SNP-probe associations) below the thresh-
old p-value of 3.861028. Stepwise linear regression was used to
prune out redundant associations of SNPs with a particular probe.
This step resulted in evidence for cis-regulation of 208 unique
Figure 3. Differential expression of genes of the interferon response. Representative genes of the interferon response pathway are shown in
panel A. From grey to red, increasing differential expression with increasing viral setpoint. Selected genes are shown in panel B. While genes
associated with interferon receptors, such as TYK2, are not differentially expressed, signaling molecules such STAT1 and interferon-stimulated genes
such as MX1 and TAP1 are significantly upregulated with increasing viral load.
doi:10.1371/journal.ppat.1000781.g003
Genome-Wide mRNA Expression and HIV
PLoS Pathogens | www.plospathogens.org 5 February 2010 | Volume 6 | Issue 2 | e1000781
probes, 157 of which were regulated by multiple SNPs in high
linkage disequilibrium between SNPs included in the analysis (51
signals of unique SNPs with a transcript, and 731 signals arising
from the regulation of 157 transcripts by multiple non-unique
SNPs). These 208 associations included 193 SNPs that modulate
190 genes in CD4+ T cells, with the overlap occurring because of
probe cross-hybridization, and also several probes detecting the
same gene (Supplementary Table S10).
This list of study-wide significant associations was compared to
the list of genes whose expression was found associated with viral
load at setpoint. Among genes under differential expression during
HIV-1 infection, several showed evidence for cis-regulation
(Supplementary Table S11) but only one, involving the
interferon stimulated OAS1, reached study-wide significance.
OAS1 was found to be regulated by an intronic SNP (rs3177979)
located near exon 6 (Supplementary Figure S1). Lower
expression was associated with the rs3177979 GG genotype.
The association was detectable in treated and untreated
individuals; however the expression level was lower in samples
from treated individuals. The association of this SNP with OAS1
transcript expression is also detectable in PBMCs collected from
uninfected controls [21].
We did not observe an association of OAS1 rs3177979 with viral
setpoint in the study (untreated) population. However, given the
potential interest of genetic polymorphism in OAS1, we also
assessed the association between rs3177979 and HIV-1 outcomes
in a large population of 2362 individuals [5]. The association
p-values were 0.05 for an association of the OAS1 SNP and viral
setpoint and 0.09 for HIV-1 disease progression, but differences
were subtle: mean HIV-1 load was 4.11 log10 viral copies/ml for
Figure 4. Transcriptome analysis in CD4+ T cells from HIV-infected individuals before and after viral suppression. Analysis was
restricted to the 260 genes found to be differently expressed by viral setpoint. Gene clusters are presented on the left. Patient clusters are presented
at the top. In red, transcriptome profile before viral suppression, and in yellow, transcriptome profile after viral suppression with effective treatment
in 37 individuals with pre- and post-treatment initiation samples. In blue, transcriptome profile of 16 elite controllers. In black, transcriptome profile
from 3 HIV-negative healthy controls (8 samples).
doi:10.1371/journal.ppat.1000781.g004
Genome-Wide mRNA Expression and HIV
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the AA genotype, 4.07 for AG, and 4.01 for GG. Because
rs3177979 is in linkage disequilibrium with rs10774671, a SNP
associated with a splicing variant ([22] and Text S1) reported to
have greater activity against West Nile virus [23], we re-genotyped
the population for this putative functional SNP, without finding
any stronger association: we have therefore no definitive evidence
of an association of cis-acting genetic variation in OAS1 with HIV-
1 viral control or disease progression.
One additional gene, RANBP1, encoding a Ran GTPase-binding
protein that interferes with Rev-mediated expression of HIV-1 [24],
presented both increased expression at higher setpoint, and a cis-
acting SNP (rs2008591) that modulates its expression (Supple-
mentary Table S11). We assessed the association between
rs2008591 and viral setpoint and disease progression in the large
population of 2362 individuals [5]. Here, rs2008591 did not
associate with viral setpoint (p= 0.45) or disease progression
(p= 0.35). Overall, these analyses identified a significant number
of cis-acting genetic variants influencing gene expression in CD4+ T
cells; however, expression polymorphism, genome-wide or among
genes that are modulated during HIV-1 infection, did not
contribute in a significant fashion to viral control.
Discussion
This study represents the largest effort to date to characterize
the mRNA expression profile in CD4+ T cells in vivo in HIV-1
infected individuals. The study population, only including
individuals with known date of seroconversion or elite controllers,
represents the complete range of viral load control: from
undetectable viral load to sustained high levels of viral replication.
The study also analyzed changes in transcriptome upon successful
antiretroviral therapy. In addition, we searched for cis-acting
variants – SNPs that would possibly associate with the observed
differences in gene expression in the course of HIV-1 infection.
Overall, changes in RNA expression reflect responses to viral
replication rather than a mechanism that might explain control of
viral replication. As such, the reactive transcriptome profile we
observed shares common responses with other viral infections, eg.
to dengue virus [25–28] (Supplementary Table S12).
In vivo HIV-1 infection results in a distinctive mRNA
transcriptome profile in CD4+ T cells that involves 260 genes in
an analysis that differentiates individuals with high and those with
low viral setpoint. Under conditions of high viral load, there is a
distinct upregulation of the interferon pathways, cell cycle and the
ubiquitin-proteasome degradation machinery. The study confirms
and extends previous analyses of in vitro infection of T cell lines, or
of CD4+ T cells in vivo that were performed on a limited number of
individuals [7–10,29,30].
This study underscores that the observed increase in transcrip-
tion of ISGs is not associated with a better control of viremia [7].
This contrasts with the reported efficacy and possible therapeutic
role of interferon (IFN-a, IFN-a2b) suggested by results from in
vitro studies, while exogenous administration of interferon in
clinical trials led to doubts about its efficacy in the clinical setting
(reviewed in [31]). Our observations lend support to the hypothesis
that interferon activation plays a deleterious role in retroviral
pathogenesis, as proposed by many recent reports (reviewed in
[31]). Elevated ISG expression is associated with disease
progression in pathogenic SIV infection of non-human primates
[32–35], while the type I interferon response subsided after peak
viral load during non-pathogenic infection [36,37]. Sedaghat et al.
[7] compared the transcriptional programs of in vivo-activated
CD4+ T cells from untreated HIV-positive individuals with those
of activated CD4+ T cells from HIV-negative individuals. From
this study, they concluded that CD4+ T cells from infected
individuals are in a hyperproliferative state that is modulated by
type I interferons, and that this would lead, during chronic
infection, to CD4+ T-cell preferential differentiation and deple-
tion. Imbeault et al. [10] suggested that interferon could lead to a
sustained increase in p53 mRNA levels and therefore to a higher
susceptibility of CD4+ T cells to pro-apoptotic signals. Herbeuval
and Shearer [31] proposed that interferon, through binding to its
receptor on primary CD4+ T cells would result in membrane
expression of the TNF-Related Apoptosis-Inducing Ligand,
TRAIL, death molecule leading to the selective death of HIV-
exposed CD4+ T cells. More recently, Sato et al. [38] showed that
type I interferon induce proliferation and exhaustion in hemato-
poietic stem cells; chronic and excessive type I interferon signaling
may cause hematopoietic stem cells reduction. Overall, interferon
response appears a poorly effective antiretroviral mechanism, and
may actually contribute to HIV-1 disease [7,39].
Among genes previously associated with HIV-1 pathogenesis,
the analysis identified a number of significant associations, in
particular for genes of the intrinsic cellular defense against
retroviruses. Many of these respond to interferon, and thus have
the same profile of increased expression with increasing viral load
as ISG. Thus, these genes appear ineffective both by their poor
specificity against HIV-1 and by the apparent limited response of
HIV-1 to increasing titration of the transcripts. We also analysed
genes issued from four genome-wide siRNA/shRNA screens
[16–19]. Fifteen genes that were associated with decreased cellular
permissiveness to infection after silencing, were upregulated with
increasing viremia in vivo in the current study. They deserve further
inspection for a role in HIV-1 pathogenesis. Although the scope of
the present work was not to complete a meta-analytical study of all
available genome-wide transcriptome studies and siRNA screens
[40], we are aware of the interest to progressively integrate large
scale datasets [41].
We aimed at identifying patterns of gene expression associated
with effective viral control. However, the nature of the analysis
could not establish whether high levels of viral replication would
lead to the observed transcriptional profile, or whether genetic
modifiers of transcriptional profile were determinants for the
control of viral replication. This was addressed first by comparing
the transcriptional profile of CD4+ T cell from elite controllers
with that of successfully treated individuals and healthy donors.
Here, we observed that the expression profile of genes associated
with active viral replication was, after effective treatment, similar
to that of individuals with spontaneous control of viral replication,
and close to that of healthy donors. This suggests that infection
drives gene expression rather than the contrary. Second, we tested
the hypothesis that genetic variants influence expression levels of
genes, thus leading to differences in viral control. The analysis
identified a number of variants that would possibly act in cis to
modulate gene expression – most notably a variant in OAS1 that
has been associated with improved control of West Nile virus
infection [23]. It may be argued that if a variant influences
expression of a gene, and if expression of that gene correlates with
viral load, then the two analyses will be partially redundant.
However, we emphasize that this approach allows for independent
information because the variation in expression of few if any genes
is determined exclusively by cis-acting variants. In addition, the
identification of strong cis-acting variants would contribute to
disentangle causation and correlation. Thus if a gene expression
correlates with viral load, it could be that the change in expression
is a response to the amount of virus, or it that the gene directly
controls the viral level. In the former case, a cis-acting variant will
show no association with viral load, whereas in the latter it will. In
Genome-Wide mRNA Expression and HIV
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the present study, none of the candidate cis-acting SNPs, or SNPs
in the implicated genes was associated with differences in viral
setpoint in a genome-wide association analysis. These results do
not contradict current evidence of mechanisms of viral control
through differences in expression levels of particular genes, most
notably CCR5 [42]. Rather, the analysis indicates that polymor-
phisms in genes implicated in the differential expression programs
do not represent a strong source of variation at the population
level.
There are a number of technical and conceptual limits to the
study. The study failed to identify a transcriptome profile
characteristic of elite controllers. This may be attributed to the
large scale approach, as the current technology covers a total of
25,440 annotated human genes. While this allows for pathway or
network analyses, it may fail in the identification of subtle
expression changes, in particular at the level of the individual gene.
On one hand, the analysis would require greater study power (ie,
additional elite controllers) to compensate the penalty of correction
for multiple testing. On the other hand, the precision of several of
analyses described earlier in this section could be improved
through the added resolution of new technology such as RNA-Seq
[31], or the targeted multiplexed measurement of gene expression
in selected pathways [43]. High-throughput deep sequencing
results in a superior dynamic range, and allows quantitative
analysis of coding and non-coding region transcripts, such as small
RNAs. It should also be pointed out that the use of cryopreserved
cells may result in changes in the transcriptome and in transcript
stability. However, this allowed the investigation of a large number
of samples from seroconverting individuals in batch analyses. We
argue that the internal consistency of the results and the general
agreement across studies supports the robust nature of the
transcription profiles that were generated.
In conclusion, while this study suggests that the generalized
upregulation of ISG, an important component of viral defense,
does not lead to consistently improved viral control throughout the
course of infection, it does not implicate any specific gene
expression network in viral control. There are several possible
explanations for these observations. First, the most important
cellular populations for determining control may be effector cells
such as CD8+ T cells or NK cells whose expression patterns have
not been evaluated here. Second, the key expression patterns that
determine eventual control may be only detectable early in
infection and thus largely missed in studies focusing on cells taken
during the setpoint period. These possibilities argue strongly that
the next phase of expression work in the study of HIV-1 control
must focus on large scale analysis of isolated populations of effector
cells taken from individuals as early in the course of infection as
possible and in a standardized fashion. We believe the approach
taken here provides a general template for such studies.
Materials and Methods
Ethics statement
Study participants were followed in the Swiss HIV Cohort
Study (www.shcs.ch). The Genetics Project of the Swiss HIV
Cohort Study was approved by the ethics committees of all
participating centers, and the permission for genomic work was
approved by the Institutional Review Board/Ethics Committee of
the University Hospital of Lausanne. Participants gave written,
informed consent for genetic testing.
Participants
198 HIV-1 infected individuals from the Swiss HIV Cohort
study with a known date of seroconversion (n= 182), or elite
controllers (n = 16) were included in the study. Seroconversion was
defined on the basis of a documented positive test and date and a
documented negative test less than two years before the first
positive test. The viral setpoint was calculated for each participant
by using a median of 4 (range 2 to 8) plasma HIV-1 RNA
determinations obtained in the absence of antiretroviral treatment
between 3 months and 3 years after seroconversion, as previously
described [2]. See Text S1 for the detail definition of viral
setpoint and of elite controllers. When available, HIV-1 infected
participants contributed samples during stable viral setpoint before
and under effective ART (median [IQR] from treatment initiation
to sample collection was 1297 (434–2730) days). In addition three
healthy blood donors provided three control samples used as
biological replicas. Quality control steps at the level of cellular
viability, RNA integrity, microarray and hybridization quality,
and data analysis led to a final number of 190 samples from 153
participants and 8 samples from 3 healthy controls (68% of valid
samples, 78% of successful recruitment). The demographic
characteristics of the patients and the flow chart of enrollment
and sample validation is presented in Text S1. Representative
examples of QC checks are presented in Supplementary
Figure S2.
Cell isolation and RNA extraction
CD4+ T cells were positively selected from frozen PBMCs
(median time [IQR] of cryopreservation was 616 [333–1448] days)
using magnetically labeled CD4 microbeads and subsequent
column purification according to the manufacturer’s protocol
(Miltenyi Biotec). CD4+ T cell purity, verified by flow cytometry,
was 95.6% (86.4–98.1%) [median (range)]. CD4+ T cell viability
was assessed by the trypan blue dye exclusion method using the
Vi-CELL (Beckman Coulter). Total RNA was extracted from
purified CD4+ T cells using mirVana miRNA isolation kit
(Ambion) according to the manufacturer’s protocol for total
RNA extraction. RNA amount was estimated by spectrophotom-
etry using the Nanodrop 1000 (Thermo Fisher). RNA quality was
determined by Agilent RNA 6000 pico kit on an Agilent 2100
Bioanalyzer. We used cryopreserved samples because of the
interest to analyse a large population of seroconverting individuals
during the precise window of stable viral setpoint. Samples were
collected between 1995 and 2007, and investigated in 2008. The
median (range) of CD4+ T cell viability for samples that were
successfully analysed was 78.5% (IQR 70.5–85.3). Viability was
minimally dependent on time of cryopreservation, and more
dependent on collection center. These covariates were included in
the analyses (see below).
Transcriptome analysis and genome-wide genotyping
200 ng of total RNA was amplified and labeled using the
Illumina TotalPrep RNA Amplification kit (Ambion). cRNA
quality was assessed by capillary electrophoresis on Agilent 2100
Bioanalyzer. Expression levels of over 48,000 mRNA transcripts
were assessed by the Human-6 v3 Expression BeadChips
(Illumina). Hybridization was carried out according to the
manufacturer’s instructions. Genome-wide SNP data had been
generated from genomic DNA using the HumanHap550 Geno-
typing BeadChip (Illumina) with 555,352 SNPs [2].
Selection of candidate genes for subanalysis
We screened the literature for genes associated with biology of
HIV-1 (reviewed in [44–47] and recent studies [15,48,49]), as well
as HIV-1 dependency factors emerging from genome-wide siRNA
screens [16–19], and genes considered polymorphic and involved
in HIV-1 pathogenesis (compiled in www.hiv-pharmacogenomics.
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org). For the three large siRNA screens, that resulted in over 600
candidates, we restricted analysis to (i) genes identified in at least
two of three screens, or to (ii) genes with SNPs that reached a
nominal significant p value in a recent genome-wide association
study of determinants of susceptibility to HIV-1 [2].
Data pre-processing
Bead summary data was output from Illumina’s BeadStudio
software without background correction, as this has previously
been shown to have detrimental effects [50]. Data pre-processing,
including a variance-stabilizing transformation [51] and robust-
spline normalization were applied as implemented in the lumi
package [52] of R. Four outlier samples identified based on
aberrant expression of control probes and aberrant median-
interquartile range values compared to other samples were
removed.
Differential expression analysis
We applied an empirical Bayes analysis approach within a linear
mixed-model framework to identify associations between variation
in gene expression and in viral setpoint. The Empirical Bayes
approach has been developed to model the variation profiles of all
genes and use that information as prior knowledge to better estimate
the variance of each gene expression [53–55]. In addition, we used a
more conservative gene-by-gene modeling approach for result
comparison with the empirical Bayes approach. We controlled for
variation caused by gender, age, CD4+ T cell viability, location of
sample collection, and laboratory batch effects. Effect of chip batch
was modeled as a random effect; all others were fixed or continuous.
All samples from untreated individuals were tested for association of
expression with viral setpoint. We used a false discovery rate (FDR)
method [56] to control for multiple testing. Probes selected for
further analysis had an FDR-adjusted p-value ,0.01. A separate
analysis compared expression in samples from treated and
untreated individuals, using a similar mixed-model approach as
above, but also incorporating viral load as a factor in the analysis.
We tested for effect of treatment by separately comparing
samples from treated individuals to each of the untreated groups,
using the limma (linear models for microarray data) package in R
with FDR adjustment as above. This analysis explicitly excluded
samples from the same individuals because the statistical approach
did not allow control for both the correlation between paired
samples and the strong correlation (batch) effect of chip. To
compare samples from treated and untreated individuals with
samples from uninfected controls, we clustered the expression
profiles for a selected group of individuals. We performed 1000
replicate clusterings on the Pearson correlation coefficient, using
the ‘‘ward’’ clustering method as implemented in the pvclust
package in R.
Pathway and network analyses
The Search Tool for the Retrieval of Interacting Genes/
Proteins (STRING) (http://string.embl.de/) was used to identify
known and predicted interactions (derived from four sources:
genomic context, high-throughput experiments, co-expression,
and previous knowledge). DAVID Bioinformatic resources
(http://david.abcc.ncifcrf.gov/) using the annotation sources
GOTERM-BP (biological process), and GOTERM-MF (molecu-
lar function) identified functional categories [57]. Ingenuity
Pathway Analysis 7.0 (IPA) (http://www.ingenuity.com/) was
used for the analysis of pathway enrichment. Analysis was
limited to genes significantly associated with viral load (FDR
p-value ,0.01).
Screen for cis-acting SNPs regulating transcript
expression levels in HIV-infected CD4+ T cells
Normalized expression data was exported for all untreated,
HIV-1 infected individuals (n = 125). Only probes that tar-
geted fully annotated genes were included in the analysis. A
principal components analysis was run to assess batch effects.
The cis-screen consisted of a scan for common SNPs, within
100 kb of the defined gene start and stop positions, for effects on
transcript expression levels. The analysis was limited to SNPs
with a minor allele frequency greater than 0.04, requiring at least
ten alleles to be present to detect associations with a low false
positive rate. This analysis was performed using a standard linear
regression, incorporating age, gender, and 11 eigenstrat axes to
correct for population stratification. In total, there were
1,330,529 tests run, therefore using a Bonferroni correction, a
p,3.861028 was used to declare a statistically significant
association.
Microarray data accession number
All microarray results have been deposited in the Gene
Expression Omnibus database (GSE18233).
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Found at: doi:10.1371/journal.ppat.1000781.s001 (7.16 MB TIF)
Figure S2 Quality control. Outlier samples were identified
based on aberrant expression of control probes and aberrant
median-interquartile range values.
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Table S3 Pathway enrichment for the 260 differentially
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HIV life cycle and pathogenesis.
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Table S8 Genes identified in the current study that have been
previously reported in genome-wide siRNA screens.
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Table S9 Overlapping genes associated with difference in viral
setpoint and associated with changes in transcriptome profile after
treatment.
Found at: doi:10.1371/journal.ppat.1000781.s011 (0.04 MB XLS)
Table S10 Study-wide significant SNP-probe associations.
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Table S11 Genes showing cis-regulation (eQTLs) in CD4 T cells
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Table S12 Genes identified in the current study that have been
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